Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM

Annals of Pharmacotherapy

Volumn 49, Issue 11, 2015, Pages 1237-1251

  Lillyblad, Matthew P ^a  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

angiotensin receptor blocker; heart failure; left ventricular systolic dysfunction; natriuretic peptide; neprilysin; sacubitril; systolic heart failure; valsartan

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CANDOXATRIL; ENALAPRIL; ENDOTHELIN 1; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; NEUROHORMONE; OMAPATRILAT; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ACUTE HEART INFARCTION; AGE; ANTIPROLIFERATIVE ACTIVITY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIURESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME METABOLISM; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; VASODILATATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEART FAILURE, SYSTOLIC;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHRONIC DISEASE; HEART FAILURE, SYSTOLIC; HUMANS; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84944625183     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015593093     Document Type: Review

References (58)

1. C.W.YancyM.JessupB.Bozkurt. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-e327.
2. D.L.MannM.R.Bristow. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837-2849.
3. D.MozaffarianE.J.BenjaminA.S.Go. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
4. L.W.StevensonR.Pande. Witness to progress. Circ Heart Fail. 2011;4:390-392.
5. V.AskoxylakisC.ThiekeS.T.Pleger. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105.
6. J.LindenfeldN.M.AlbertJ.P.Boehmer. HFSA 2010 Comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-e194.
7. J.J.McMurrayM.PackerA.S.Desai. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
8. J.N.CohnD.G.ArchibaldS.Ziesche. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
9. D.P.LipkinP.A.Poole-Wilson. Treatment of chronic heart failure: a review of recent drug trials. Br Med J (Clin Res Ed). 1985;291:993-996.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
11. J.N.CohnG.JohnsonS.Ziesche. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
12. M.Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
13. S.A.Atlas. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;(8, suppl B):9-20.
14. C.R.BenedictD.E.JohnstoneD.H.Weiner. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994;6:1410-1420.
15. F.FuchsS.H.Smith. Calcium, cross-bridges, and the Frank-Starling Relationship. News Physiol Sci. 2001;16:5-10.
16. M.A.PfefferJ.J.McMurrayE.J.Velazquez. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
17. C.B.GrangerJ.J.McMurrayS.Yusuf. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
18. A.P.MaggioniI.AnandS.O.Gottlieb. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-1421.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
20. B.PittR.SegalF.A.Martinez. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
21. B.PittP.A.Poole-WilsonR.Segal. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
22. J.J.McMurrayJ.OstergrenK.Swedberg. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
23. J.N.CohnG.Tognoni; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
24. J.J.McMurrayS.AdamopoulosS.D.Anker. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
25. M.PackerM.R.BristowJ.N.Cohn. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
26. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
27. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
28. C.BorghiS.BoschiE.Ambrosioni. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:40-45.
29. B.PittF.ZannadW.J.Remme. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
30. F.ZannadJ.J.McMurrayH.Krum. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
31. L.R.PotterS.Abbey-HoschD.M.Dickey. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
32. E.R.LevinD.G.GardnerW.K.Samson. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
33. J.KoglinS.PehlivanliM.SchwaiblmairM.VogeserP.CremerW.vonScheidt. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941.
34. T.Inagami. Atrial natriuretic factor as a volume regulator. J Clin Pharmacol. 1994;34:424-426.
35. A.M.Richards. The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart. 1996;76:36-44.
36. W.L.MillerM.A.PhelpsC.M.Wood. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355-360.
37. S.L.StephensonA.J.Kenny. Metabolism of neuropeptides: hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241:237-247.
38. G.McDowellD.P.Nicholls. The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans. Cardiovasc Drug Rev. 2000;18:259-270.
39. D.R.McCleanH.IkramS.Mehta. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol. 2002;39:2034-2041.
40. M.PackerR.M.CaliffM.A.Konstam. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
41. J.B.KostisM.PackerH.R.BlackR.SchmiederD.HenryE.Levy. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
42. R.M.FryerJ.SegretiP.N.Banfor. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153:947-955.
43. S.TohM.E.ReichmanM.Houstoun. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582-1589.
44. J.GuA.NoeP.Chandra. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414.
45. J.J.McMurrayM.PackerA.S.Desai. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073.
46. M.PackerJ.J.McMurrayA.S.Desai. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61.
47. J.N.CohnS.ZiescheR.Smith. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856-863.
48. M.PackerC.M.O’ConnorJ.K.Ghali. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-1114.
49. J.L.RouleauJ.W.WarnicaJ.H.Burgess. Prazosin and congestive heart failure: short- and long-term therapy. Am J Med. 1981;71:147-152.
50. W.H.TangJ.P.GirodM.J.Lee. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964-2966.
51. A.ClericoA.GiannoniS.VittoriniM.Emdin. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17:81-96.
52. L.M.RuilopeA.DukatM.BöhmY.LacourcièreJ.GongM.P.Lefkowitz. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
53. D.L.DriesD.V.ExnerM.J.DomanskiB.GreenbergL.W.Stevenson. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
54. J.M.TestaniS.E.KimmelD.L.DriesS.G.Coca. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685-691.
55. M.A.DevoyC.R.TomsonM.E.EdmundsJ.FeehallyJ.Walls. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med. 1992;232:493-498.
56. M.R.BristowE.M.GilbertW.T.Abraham. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807-2816.
57. M.PackerP.A.Poole-WilsonP.W.Armstrong. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
58. D.N.JuurlinkM.M.MamdaniD.S.Lee. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.